The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Harris Erik since 2020.
This trader's CIK number is 1780113.
At the time of last reporting, Harris Erik was the EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc.. (stock ticker symbol RARE).
Also see all insider trading activities at Ultragenyx Pharmaceutical Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RARE | 0 | $0 | 15,103 | $635,836 | 0 | $0 |
| 2024 | RARE | 0 | $0 | 4,768 | $256,327 | 0 | $0 |
| 2023 | RARE | 0 | $0 | 9,969 | $408,257 | 0 | $0 |
| 2022 | RARE | 0 | $0 | 3,008 | $196,900 | 0 | $0 |
| 2021 | RARE | 0 | $0 | 7,467 | $806,651 | 0 | $0 |
| 2020 | RARE | 0 | $0 | 220 | $19,360 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-03 | RARE | Sale | 15,103 | 42.10 | 635,836 |
| 2024-03-01 | RARE | Sale | 4,768 | 53.76 | 256,327 |
| 2023-09-05 | RARE | Sale | 6,000 | 37.96 | 227,760 |
| 2023-06-19 | RARE | Sale | 305 | 48.20 | 14,701 |
| 2023-03-01 | RARE | Sale | 3,664 | 45.25 | 165,796 |
| 2022-06-19 | RARE | Sale | 295 | 54.78 | 16,160 |
| 2022-03-01 | RARE | Sale | 2,713 | 66.62 | 180,740 |
| 2021-10-14 | RARE | Sale | 303 | 81.14 | 24,585 |
| 2021-07-06 | RARE | Sale | 375 | 91.53 | 34,323 |
| 2021-05-06 | RARE | Sale | 307 | 113.68 | 34,899 |
| 2021-05-07 | RARE | Sale | 393 | 113.67 | 44,672 |
| 2021-04-20 | RARE | Sale | 396 | 104.28 | 41,294 |
| 2021-03-01 | RARE | Sale | 2,470 | 138.17 | 341,279 |
| 2021-03-02 | RARE | Sale | 707 | 138.16 | 97,679 |
| 2020-06-03 | RARE | Sale | 2,516 | 74.69 | 187,920 |
| 2020-10-14 | RARE | Sale | 220 | 88.00 | 19,360 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Harris Erik (EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.